ABSTRACT
+

25
+ T reg immune suppression have been significantly less studied. We previously showed that polyclonal T cells can acquire antigen-specific targeting activity through arming with exosomal peptide-MHC (pMHC). In this study, we assessed the suppressive effect of CD8 
+ T regs also suppress activation of self-reactive T effector cells in a non-Ag-specific manner via cell-to-cell contact fashion [5, 6] . In vitro, they exert their immune suppression by inhibiting IL-2R expression in target T cells, which is achieved through the expression of membranebound CTLA-4 and TGF-b on T regs but not through the secretion of suppressive cytokines [5, 6] . Recently, it was demonstrated that CD8 + 25 + T regs are also essential for the inhibition of follicular CD4 + Th cells, which support self-tolerance [7] , and that CD28 has an important role in the recognition of target cells for the suppression of CD8 + 25 + T regs [8] . In addition, it was shown that the immunosuppressive effect of CD8 + 
+ T regs is less potent than that of CD4 + 25 + T regs [9] . However, the immune mechanism responsible for CD8 + 25 + T reg -mediated suppression has not been studied extensively [10] .
DCs release Ag-presenting vesicles called exosomes, which contain Ag peptide-presenting pMHC-I and pMHC-II, and carry costimulatory (CD80 and CD86) molecules, which represent the molecular machinery required for generating T cell responses [11] . We previously demonstrated that nonspecific polyclonal T cells became capable of stimulating Ag-specific CTL responses via exosomal pMHC-I targeting, when acquiring Ag-specific EXOs [11] . This prompted us to assume that immunosuppression by natural polyclonal CD8 + 25 + T regs may also be converted from their original nonspecificity to an Ag-specific approach when they are armed with Ag-specific EXO pMHC complexes.
In this investigation, we purified polyclonal CD8 + 25 + T regs from C57BL/6 mouse splenocytes and expanded them in culture, using anti-CD3/CD28 Ab-coated microbeads and IL-2. We initially assessed the suppressive effect of CD8 + 
+ T regs through in vitro experiments and found that CD8 + 
+ T regs inhibited T cell proliferation in a cell-contact fashion but independent of suppressive IL-10, TGF-b, and 
+ T regs , armed with OVA-specific exosomal pMHC-II and pMHC-I complexes, exerted the enhanced inhibition of OVAspecific CTL responses in the priming and the effector phases, respectively. , and perforin 2/2 KO mice were all obtained from the Jackson Laboratory (Bar Harbor, ME, USA). The OT I/B6.1 (CD45.1) mice were prepared by breeding OT I with B6.1 mice. All mice were treated according to animal care committee guidelines of the University of Saskatchewan (Saskatoon, SK, Canada).
MATERIALS AND METHODS
Reagents
Preparation of immune cells and EXOs
Naive CD4 + and CD8 + T cells were purified from WT B6 or OT I/B6.1 mouse splenocytes, and DCs were prepared by culturing mouse bone marrow cells in medium containing GM-CSF (20 ng/ml) and IL-4 (20 ng/ml) for 6 d. as previously described [14] . Those mature DCs were then pulsed with OVA protein (0.1 mg/ml) for 16 h and termed DC OVA [14] . The OVAspecific CTLs were prepared by cultivation of naïve OT I/B6.1 CD8 + T cells with irradiated (3000 rad) DC OVA at a ratio of (3:1) for 3 d [14] . Naive CD8 in culture medium containing GM-CSF/IL-4 (10 ng/ml) and IL-4 (10 ng/ml), respectively, for 16 h because GM-CSF and IL-4 can promote DC and T cell survival, respectively [15] . DCs and naïve CD4 + T cells or CTLs (CD45.1) were then purified with MACS CD11c 2 and CD4 2 or CD45.1 microbeads, respectively (Miltenyi Biotech). The dead T reg -treated CTLs were removed through Ficoll-gradient centrifugation. cytokine secretion using ELISA kits [16] . In another set of experiments, culture supernatants derived from a mixture of MF7 or RF1370 cells with T reg/EXO or T reg=EXOðKb 2 = 2 Þ or T reg=EXOðIab 2 = 2 Þ cells were measured for IL-2 secretion using ELISA kits [13] .
In vitro T cell proliferation assays
RT-PCR analysis
Naïve CD4 + T and RNA isolation was performed using RNeasy Plus Mini Kit (Qiagen, Toronto, ON, Canada), and cDNA was then synthesized immediately using the RT 2 First Strand Kit (Qiagen). RT-PCR was carried out with RT 2 SYBR Green qPCR Mastermix (Qiagen) using a StepOnePlus Real-time PCR system (Thermo Fisher Scientific) [18] . A panel of primers specific for T cell anergy-associated genes (Ikaros, Grail, Casp3, EGR2, Grg4, and Itch) were synthesized [19] . Expression of each gene was normalized to b-actin [18] .
Western blotting
Cell lysates (10 mg/lane) were loaded onto 12% acrylamide gels, subjected to SDS-PAGE, and was subsequently transferred onto nitrocellulose membrane (Millipore, Bedford, MA). The membrane was blocked by incubation for 2 h at room temperature with ODYSSEY blocking buffer (LI-COR Biosciences, Lincoln, NE, USA) and immunoblotted with Abs specific for Egr2 and b-actin at 4°C overnight, followed by incubation with goat anti-rabbit IRDye800CW, and scanned using the ODYSSEY instrument, according to manufacturer's instruction [18] .
Cytotoxicity assays
To assess the cytolytic effect of OVA-specific CTLs, we performed an in vitro cytotoxicity assay, in which OVA-specific CTLs or T reg -treated CTLs and OVAexpressing LLC OVA tumor cells were used as effector and target cells, respectively, in an MTT assay, as previously described [20] . To assess the cytolytic effect of T regs , we performed another in vitro cytotoxicity assay, in which the fluorogenic GB activity in target cells was measured with a GranToxiLux kit (OncoImmunin, Gaithersburg, MD, USA). Briefly, 4 3 10 6
CTLs (target cells) were labeled with fluorescent cell-linker dye TFL4 and incubated with 1 3 10 6 CD8 + 25 + T reg or T reg -perforin 2/2 cells lacking perforin (effector cells) for 3 h. After incubation with a fluorogenic substrate for GB, cells were analyzed by flow cytometry for GB activity [15] . In addition, we performed an in vivo cytotoxicity assay for assessment of the killing activity of DC OVA -induced CD8 + CTLs, in which C57BL/6 mice were i. 
Electron microscopy
EXOs were fixed in 4% paraformaldehyde. The pellets were then loaded onto carbon-coated formvar grids. The EXO sample-loaded grids were stained with saturated aqueous uranyl and examined with a JEOL 1200EX electron microscope (JEOL, USA, Peabody, MA, USA) at 60 kV.
Animal studies 
Statistical analyses
Statistical analyses were performed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) to perform log-rank test in animal-survival analysis and were used for unpaired, 2-tailed Student's t test in all other data [21] . P values , 0.05 are considered statistically significant. (Fig. 1A) . CD8 + 25 + T regs were expanded in vitro with IL-2 and CD3/CD28 beads for T cell activation, and were, then, analyzed by flow cytometry and ELISA. We found that CD8 + 25 + T regs expressed bona fide T reg markers (such as cell-surface CD25, CD103, GITR, and CTLA-4), and intracellular Foxp3 (93%), perforin and GB (Fig. 1B and C) . They also secreted immunosuppressive cytokines, including IL-10 (1.5 ng/ml) and TGF-b (0.8 ng/ml), as well as inflammatory cytokines, IFN-g (4.0 ng/ml), and TNF-a (3.0 ng/ml), but no IL-4.
RESULTS
CD8
CD8+25+ Tregs inhibit DC-stimulated T cell proliferation via cell-to-cell contact but independent of CTLA-4, IL-10, and TGF-b
To assess the inhibitory effect of CD8 + 
25
+ T regs , we performed an in vitro T cell proliferation assay using CFSE-labeled naive CD4 + or CD8 + T cells. This dye is equally partitioned upon cell division, allowing the generation of proliferation profiles. As shown in Fig.  1D T cell population subset had no influence on in vitro T cell proliferation (data not shown). To assess the cell-to-cell contact dependency of the effect, we used transwell plates to separate CFSE-labeled naive T cells and T regs . We found that T regs in transwells did not show any inhibitory effect, indicating that the suppressive activity of CD8 + 25 + T regs required the cell-to-cell contact formation. To assess the potential molecular mechanisms for T reg -mediated inhibition, we included blocking reagents, such as anti-CTLA-4, anti-IL-10, or anti-TGF-b Abs in our experiments. We found that T reg -induced inhibition was not affected by those blocking reagents (Fig. 1E) , indicating that CD8 + 25 + T regtriggered inhibition was mediated by neither secretion of immune suppressive cytokines, such as IL-10 and TGF-b, nor expression of the well-described suppressive molecule CTLA-4.
CD8
+ 25 + T regs induce T cell anergy CD4 + 25 + T regs have been reported to have an inhibitory role by rendering naive T cells functionally anergic [23] . However, the underlying mechanism of their action remains elusive. To investigate that mechanism, we performed an RT-PCR analysis to measure expression of 6 T cell, anergy-associated genes at the transcriptional level, and the Egr2 gene was found to be 4-folds more active in CD8 + 
25
+ T reg -treated naïve CD4 + T regs compared with control, untreated, naïve CD4 + T cells ( Fig. 2A) down-regulated expression of DC maturation markers, such as CD80, CD86, and I-A b (Fig. 3A) and inflammatory cytokines, such as IL-6, IFN-g, and TNF-a but up-regulated suppressive expression of immunosuppressing IL-10 (Fig. 3B) , indicating that CD8 + 
+ T regs rendered DCs immature. To assess their stimulatory effect on naïve T cells, we performed a T cell proliferation assay using T reg -treated DCs as stimulators. We found that T regtreated DCs lost their stimulatory effect on T cell proliferation (Fig. 3C) (Fig. 4A) . CTLs exert their cytolytic activity on tumor cells via cytolytic granule perforin-mediated apoptosis [24] . To assess whether CD8 + 25 + T regs modulate perforin production and degranulation in CTLs, we used flow cytometry and found that the intracellular expression of cytolytic granule perforin and the cell-surface expression of the granulation marker CD107a were strongly suppressed in T reg -treated CTLs (Fig. 4B) 
+ T regs exert their cytolytic activity toward CTLs via GB-perforin/M6PR-mediated apoptosis, leading to CD8 + T cell contraction in the immune response [25] . We demonstrated that the effector CTLs expressed cell-surface M6PR (Fig. 4C) . To assess whether CD8 + 25 + T regs also suppressed CTLs via perforin-mediated CTL apoptosis, we then performed an in vitro cytotoxicity assay in which CD8 + 25 + T regs and CTLs labeled with TFL2 fluorescence were used as effectors and target cells, respectively. We demonstrated a significant increase of CTL apoptosis by CD8 + 25 + T reg treatment from 3.66% spontaneous apoptosis to 17.20% T reg -induced apoptosis (Fig. 4D) . To assess the molecular mechanism for T reg -induced killing, we used CD8 + 25 + T reg -perforin 2/2 lacking perforin expression as effectors and demonstrated that CD8 + 25 + T reg -induced effector apoptosis was significantly decreased under this experimental condition (Fig. 4D) 
CD8
+ T cells, accounting for 3.1% in the total CD8 + T cell population in C57BL/6 mice ( Fig. 5A[b] ). However, PE-H-2K b / OVAI tetramer-positive CD8 + T cell responses in mice with coinjection of T regs dropped to 2.2% in the total CD8 + T cell population (Fig. 5A[c] Fig. 5B [c]; 26% in Fig. 5B[d] ). However, the DC OVA -stimulated CTL cytolytic effect was maintained in mice administered with T reg -perforin 2/2 on d 5 after DC OVA immunization (Fig. 5A[e] ). To assess whether CD8 + 25 + T regs suppressed DC OVA -induced antitumor immunity, we s.c. immunized mice with DC OVA on their right thighs, and i.v. injected mice with CD8 + 25 + T regs in the priming and the effector phases, as described above. Several days after immunization, mice were s.c. injected with OVA-expressing LLC OVA tumor cells on their left thighs. We found that DC OVA immunization protected 10 of 10 mice from LLC OVA tumor challenge, whereas administration of T regs in the priming or effector phases (at d 0 or 5 of the DC OVA immunization), significantly reduced DC OVAinduced protective immunity, from 10 of 10 mice to 7 of 10 or 4 of 10 (Fig. 5C) . Interestingly, we also showed that the T reg suppression of DC OVA -induced protective immunity in mice administered with T reg -perforin 2/2 on d 5 after DC OVA immunization was abolished (Fig. 5C ), indicating that CD8 + 25 + T regs inhibited DC OVA -induced protective immunity in the effector phase via the perforin-mediated CTL apoptosis.
CD8 + 25 + T regs armed with exosomal pMHC-I and pMHC-II complexes
We previously demonstrated that nonspecific polyclonal T cells stimulated Ag-specific CTL responses when subjected to exosomal targeting of Ag-specific pMHC-I [11]. To assess the potential effect of exosomal pMHC targeting on polyclonal CD8 + 25 + T regs , we first purified EXOs from OVA-specific DC OVA culture supernatants by ultracentrifugation and showed that EXOs had a typical exosomal "saucer" or round shape with a diameter of 50-100 nm by electron microscopic analysis (Fig. 6A) and expressed exosomal markers LAMP-1 and CD9 (Fig. 6B) [26] . We then generated CD8 To assess the functional effect of exosomal pMHC complexes of T reg/EXO , we cocultured T reg/EXO cells with RF3370 and MF4 T cell hybridoma cells expressing OVA-specific TCR for pMHC-I and pMHC-II complexes, respectively, followed by measurement of IL-2 production in RF3370 and MF4 cell culture supernatants. We found that T reg/EXO cells, similar to DC OVA stimulated IL-2 secretion of RF3370 and MF4 cells, indicating that T reg/EXO cells express functional pMHC-I and pMHC-II complexes (Fig. 6C) . Because we wanted to direct the effect of exosomal pMHC-I and pMHC-II of T reg/EXO cells, we also generated and purified EXO ( expression , respectively. Based on those EXOs, we further generated T reg=EXOðKb 2 = 2 Þ and cells to stimulate MF7 and RF3370 for measurement of IL-2 production, respectively. We demonstrated that T reg=EXOðKb 2 = 2 Þ cells only stimulated MF7, but not RF3370, to secrete IL-2, whereas T reg=EXOðIab 2 = 2 Þ cells only stimulated RF3370, but not MF7, to secrete IL-2 (Fig. 6C) , indicating that T reg=EXOðKb 2 = 2 Þ cells expressed pMHC-II, but not pMHC-I or vice versa, for T reg=EXOðKb 2 = 2 Þ *** cells.
Exosomal pMHC-II and pMHC-I arming enhances CD8 + 25 + T reg suppression of CTL responses in priming and effector phases, respectively
To assess whether pMHC arming affected T reg -mediated suppression of CTL responses, we injected T reg , T reg/EXO , T reg=EXOðKb 2 = 2 Þ , or T reg=EXOðIab 2 = 2 Þ cells to DC OVA -immunized mice on d 0 and 5, respectively, and measured CTL responses on d 6 after immunization. Similar to the findings shown in Fig.  5A , we observed that the administration of T regs on d 0 or 5 after DC OVA immunization reduced DC OVA -stimulated CTL responses (Fig. 6D[a] vs. Fig. 6D[b] or Fig. 6D[f] ). Interestingly, we found that the administration of EXO-armed T reg (T reg/EXO ) cells on d 0 or 5 reduced DC OVA -stimulated CTL responses significantly more than the administration of T regs (Fig. 6D[b] vs. Fig. 6D[c] , or bar Fig. 6D[f] vs. Fig. 6D[g] ) did, indicating that pMHC arming of T regs was able to enhance the T reg suppression of CTL responses. To address whether pMHC-I or pMHC-II arming affects T reg suppression, we performed similar experiments using T reg=EXOðKb 2 = 2 Þ or T reg=EXOðIab 2 = 2 Þ specifically lacking pMHC-I or pMHC-II, and found that T reg=EXOðKb 2 = 2 Þ , but not T reg=EXOðIab 2 = 2 Þ , administered on d 0 (Fig. 6D[c] vs. Fig.   6D [e]) mimicked the action of T reg/EXO. In contrast, T reg=EXOðIab 2 = 2 Þ, but not T reg=EXOðKb 2 = 2 Þ , administered on d 5 (Fig. 6D[g] vs. Fig. 6D[h] ) maintained the efficiency of T reg/EXO in suppressing DC OVA -stimulated CTL responses, indicating that exosomal pMHC-II and pMHC-I arming enhanced CD8 + 25 + T reg suppression of CTL responses in priming and effector phases, respectively.
DISCUSSION
The natural, nonspecific CD8ab + 25 + Foxp3 + T reg has an important role in the maintenance of self-tolerance [27] , control of autoimmunity, and suppression of antitumor immunity via the recognition of normal self-antigens [28] and tumor-associated Ags [29] . In this study, we expanded natural CD8 + 25 + T regs using IL-2 and CD3/CD28 microbeads, as previously described [27] . We demonstrate that the CD8 + 
25
+ T regs expressed bona fide T reg markers (CD25, GITR, CTLA-4, and Foxp3), perforin, and GB, which is consistent with a recent report on CD8 + 25 + T regs [9] . In addition, the CD8 + 25 + T regs also secreted immune-suppressive cytokines, such as IL-10 and TGF-b, as well as some inflammatory cytokines, IFN-g, and TNF-a. To assess the inhibitory effect of CD8 + 25 + T regs , we performed an in vitro T cell proliferation assay using CFSE-labeled naive CD4 + or CD8 + T cells stimulated by DCs in the presence of different amounts of CD8 + 25 + T regs . We found that CD8 To dissect the molecular mechanism of the observed inhibitory effect, we analyzed CD8 + 
+ T regs were found to execute the cytolytic activity to CTLs via the cytolytic granules GB and perforin [33] . However, the molecular pathway involved in the killing of CTLs is not yet clear. M6PR acts as the cell-surface receptor for serineprotease GB [34] . Cytolytic granules (perforin and GB) that are complexed with serglycin are delivered into target cells through binding of the GB M6P moiety to the M6PR of target cells [35] , leading to endocytosis of the complexes and active cell apoptosis [34] . To assess a potential killing activity of CD8 + 25 + T regs , we performed an in vitro cytotoxicity assay, in which CD8 + 25 + T regs and perforin 2/2 T regs and M6PR-expressing CD8 + T cells were used as effectors and target cells, respectively. We determined that CD8 + 
+ T regs eliminated effector T cells through perforinmediated apoptosis. CD107a became exposed on the cell surface because of the degranulation of cytolytic granules (GB and perforin) in CD8 + T cells and, thus, is a surrogate marker for CTL cytotoxicity [36] . [39, 40] , indicating that augmenting CD8 + 25 + T reg function in the autoantigenspecific manner is likely to be beneficial for treating autoimmunity [41] . As a proof-of-concept, Ag-specific TCRs or chimeric receptors can be introduced into polyclonal T regs via cotransduction of TCR-a and TCR-b chains [42] or by lentiviral vectors encoding both TCR-a and TCR-b chains as a single transcript [43] , conferring on them the ability to potently suppress Ag-specific CTL responses [44] [45] [46] [47] . However, some critical disadvantages associated with that approach may limit its clinical use. For example, those approaches typically result in low expression of the engineered TCR-a and TCR-b pairs because of limited transduction efficiencies or mispairing with endogenous TCR chains [43] .
Alternatively, redirecting Ag specificity to nonspecific polyclonal T cells can be achieved via the acquisition of exosomal pMHC complexes. We have previously demonstrated that polyclonal CD4 + EAE is a rodent model that has been valuable for the characterization of immunopathogenic processes mimicking human multiple sclerosis. In a therapeutic context, there is accumulating evidence that natural CD4 + 25 + T reg populations expanded in vitro or in vivo can be used for suppressing EAE [49] and preventing autoimmune diseases [50, 51] AUTHORSHIP Y.Z. and J.X. designed the experiments. C.M., X.Z., L.W., A.X., K.A.A., X.P., and R.C. performed the experiments. C.M., Y.Z., and J.X. analyzed the data. C.M. and J.X. wrote the manuscript, and A.F. and J.H. provided manuscript editing and fine tuning.
